ABSTRACT
BACKGROUND There is a rising concern about treatment-associated cardiotoxicities in breast cancer patients.
OBJECTIVES This study aimed to determine the time- and treatment-specific incidence of arrhythmia, heart failure and ischemic heart disease in women diagnosed with breast cancer.
METHODS A register-based matched cohort study was conducted including 8338 breast cancer patients diagnosed from 2001-2008 in the Stockholm-Gotland region and followed-up until 2017. Overall and time dependent risks of arrhythmia, ischemic heart disease and heart failure in breast cancer patients were assessed using flexible parametric models as compared to matched controls from general population. Treatment-specific effects were estimated in breast cancer patients using Cox model.
RESULTS During a median follow-up of 10.8 years, the hazard ratios for arrhythmia, heart failure and ischemic heart disease, were 1.27 (95% CI = 1.18-1.37), 1.38 (95% CI = 1.23-1.55), and 0.93 (95% CI = 0.84-1.03), respectively. Time-dependent analyses revealed long-term increased risks of arrhythmia, and heart failure in breast cancer patients compared to matched controls. The risk of ischemic heart disease was only elevated in the first year after cancer diagnosis. Trastuzumab and anthracyclines were associated with increased risk of heart failure. Aromatase inhibitors, but not tamoxifen, were associated with risk of ischemic heart disease. No increased risk of heart disease was identified following loco-regional radiotherapy.
CONCLUSIONS Administration of systemic adjuvant therapies appear to be associated with increased risks of heart disease. The risk estimates observed in this study may serve as reference to aid adjuvant therapy decision-making and patient counseling in oncology practices.
Competing Interest Statement
Nirmala Bhoo Pathy: NBP received educational grants to their institution from Novartis, Pfizer, AIA Bhd and Pharmaceutical Association of Malaysia. NBP has received speaker's fees from Novartis, Pfizer and Roche, and received travel support from Roche and Pharmaceutical Association of Malaysia to attend conferences in 2018 and 2019. NBP has served on the advisory board of Pfizer Asia Pacific, Malaysia (2017/18 year), and been a committee member for Together Against Cancer (NGO) (2018 and 2019). Roche Diagnostics also provided NBP with research material, namely COVID-19 total antibody kits. The author has no other competing interests to declare. Jonas Bergh: JB's research was supported by payments from Amgen, AstraZeneca, Bayer, Merck, Roche and Sanofi-Aventis to their institution, along with payments from non-profit organisations (Swedish Cancer Society and Knut Alice Wallenberg) and the Swedish Research Council. JB also gave lectures to Astra Zeneca and Roche (no personal payment was received for these). JB is a scientific advisor to The Medical product agency and to EMA, and is a representative of Swedish Breast Cancer Group. The author has no other competing interests to declare. Jonas Ludvigsson: JFL coordinates a study on behalf of the Swedish IBD quality register (SWIBREG). This study has received funding from Janssen corporation. The author has no other competing interests to declare.
Funding Statement
This work was supported by the Swedish Research Council [grant no: 2018-02547]; Swedish Cancer Society [grant no: CAN-19-0266] and FORTE [grant no: 2016-00081]. HY was supported by Startup Fund for high-level talents of Fujian Medical University [grant no: XRCZX2020007] and Startup Fund for scientific research, Fujian Medical University [grant no: 2019QH1002]. NBP was supported by the University of Malaya Impact-Oriented Interdisciplinary Research Grant Programme [grant no: IIRG006C-19HWB]. WB was partly supported by China Scholarship council. Dr Ludvigsson coordinates a study on behalf of the Swedish IBD quality register (SWIBREG), which has received funding from Janssen corporation. The funders had no role in the study design, data collection, analyses, data interpretation, writing the manuscript, or in the decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Regional Ethical Review Board in Stockholm (Dnr 2009/254-31/4).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
Data Availability: The data used in this study are owned by the Swedish National Board of Health and Welfare and Statistics Sweden. According to Swedish law and GDPR, the authors are not able to make the dataset publicly available. Any researchers (including international researchers) interested in obtaining the data can do so by the following steps: 1) apply for ethical approval from their local ethical review boards; 2) contact the Swedish National Board of Health and Welfare and/or Statistics Sweden with the ethical approval and make a formal application of use of register data.
LIST OF ABBREVIATIONS
- ICD
- International Classification of Diseases
- CI
- confidence intervals
- HR
- hazard ratio
- CCI
- Charlson Comorbidity Index
